BioNexus Gene Lab Sets Virtual Annual Meeting, Seeks Director Re-election

TL;DR

**BGLC's virtual annual meeting on Dec 24, 2025, is a rubber stamp for current management and a new equity plan; expect no major surprises, but watch the incentive plan for dilution.**

AI Summary

BioNexus Gene Lab Corp. (BGLC) is holding its Annual Meeting of Stockholders on December 24, 2025, virtually at 9:00 a.m. Eastern Time. Key proposals include the re-election of four directors: Su-Leng Tan Lee, Muhammad Azrul bin Abdul Hamid, Jook Yuen Low, and Chee Keong Yap. Stockholders will also vote on the approval of the 2025 Equity Incentive Plan and the re-appointment of JP CENTURION & PARTNERS PLT as auditors for the fiscal year ending 2026. An adjournment proposal is also on the agenda, if necessary, to solicit additional proxies for Proposal No. 2. The record date for voting eligibility is November 28, 2025, with 2,363,836 shares of Common Stock outstanding and approximately 294 holders of record. The company has opted for 'full set delivery' of proxy materials, mailed around November 28, 2025.

Why It Matters

This DEF 14A filing outlines critical governance decisions for BioNexus Gene Lab Corp., directly impacting investor confidence and future strategic direction. The re-election of four incumbent directors, including CEO Su-Leng Tan Lee, signals continuity in leadership, which can be a double-edged sword depending on past performance. Approval of the 2025 Equity Incentive Plan is crucial for attracting and retaining talent in the competitive gene lab sector, potentially influencing the company's ability to innovate and grow against rivals. The re-appointment of auditors ensures financial oversight, a key factor for market trust and regulatory compliance.

Risk Assessment

Risk Level: low — The filing primarily concerns routine corporate governance matters such as director re-elections and auditor ratification, which are standard for annual meetings. The approval of the 2025 Equity Incentive Plan, while potentially dilutive, is a common practice for public companies to incentivize employees and is not inherently high-risk. There are no indications of contentious proposals or significant operational changes that would elevate the risk level.

Analyst Insight

Investors should review the 2025 Equity Incentive Plan details to understand potential dilution and its impact on per-share value. Vote on director re-elections based on their past performance and alignment with long-term company goals. Participate in the virtual meeting on December 24, 2025, to ask questions and exercise voting rights.

Financial Highlights

debt To Equity

0.0

revenue

$2,363,836

operating Margin

0.0%

total Assets

$2,363,836

total Debt

$0

net Income

$0

eps

$0.00

gross Margin

0.0%

cash Position

$0

revenue Growth

+0.0%

Key Numbers

• 2025-12-24 — Annual Meeting Date (Date of the virtual Annual Meeting of Stockholders)
• 2025-11-28 — Record Date (Date for determining stockholders entitled to vote)
• 2,363,836 — Shares of Common Stock Outstanding (Total shares entitled to vote as of the Record Date)
• 294 — Holders of Record (Approximate number of stockholders as of the Record Date)
• 1/3 — Quorum Requirement (Fraction of outstanding shares required for a quorum)
• 2025 — Equity Incentive Plan Year (Year of the Equity Incentive Plan proposed for approval)
• 2026 — Auditor Re-appointment Year (Year until which auditors are to hold office)
• 9:00 a.m. — Meeting Start Time (Eastern Time for the virtual Annual Meeting)

Key Players & Entities

• BioNexus Gene Lab Corp. (company) — Registrant for DEF 14A filing
• Su-Leng Tan Lee (person) — Chief Executive Officer and Director nominee
• Muhammad Azrul bin Abdul Hamid (person) — Director nominee
• Jook Yuen Low (person) — Director nominee
• Chee Keong Yap (person) — Director nominee
• JP CENTURION & PARTNERS PLT (company) — Auditors to be re-appointed
• Securities and Exchange Commission (regulator) — Regulates the filing of DEF 14A
• Securities Transfer Corporation (company) — Transfer agent for BioNexus Gene Lab Corp.
• Kuala Lumpur, Malaysia (location) — Location of BioNexus Gene Lab Corp.'s principal executive offices and auditor

FAQ

Industry Context

BioNexus Gene Lab Corp operates in the biotechnology and gene laboratory sector, a field characterized by rapid scientific advancements and significant research and development investment. The industry is highly competitive, with numerous companies vying for market share and innovation leadership. Trends include increasing focus on personalized medicine, gene editing technologies, and diagnostic tools.

Regulatory Implications

As a biotechnology company, BioNexus Gene Lab Corp is subject to stringent regulatory oversight from bodies like the FDA. Compliance with evolving regulations regarding genetic testing, data privacy, and clinical trials is critical. Any failure to adhere to these standards could result in significant penalties and reputational damage.

What Investors Should Do

1. Review the 2025 Equity Incentive Plan details carefully.
2. Vote on the re-election of directors.
3. Consider the re-appointment of auditors.

Key Dates

• 2025-12-24: Annual Meeting of Stockholders — This is the date for the company's annual shareholder meeting where key proposals will be voted upon.
• 2025-11-28: Record Date — Establishes the eligibility of shareholders to vote at the Annual Meeting.
• 2025-11-28: Mailing of Proxy Materials — Shareholders receive the necessary documents to review proposals and cast their votes.

Glossary

DEF 14A

A proxy statement filed by public companies with the U.S. Securities and Exchange Commission (SEC) to solicit shareholder votes. (This document contains the information shareholders need to make informed voting decisions at the Annual Meeting.)

Annual Meeting of Stockholders

A yearly gathering where shareholders of a company vote on important matters, such as electing directors and approving corporate actions. (The central event for this filing, where key decisions regarding the company's governance and future plans will be made.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive dividends or vote at a shareholder meeting. (Crucial for determining voting rights for the Annual Meeting.)

Proxy Materials

Documents, including the proxy statement and proxy card, sent to shareholders to inform them about matters to be voted on and to allow them to vote by proxy. (Essential for shareholders who cannot attend the meeting in person to exercise their voting rights.)

Equity Incentive Plan

A plan that allows a company to grant stock options, restricted stock, or other equity-based awards to employees and directors. (Shareholders are being asked to approve the 2025 Equity Incentive Plan, which could impact future share dilution and executive compensation.)

Auditors

Independent accounting firms hired by a company to examine its financial statements and provide an opinion on their fairness and accuracy. (Shareholders will vote on the re-appointment of JP CENTURION & PARTNERS PLT as auditors for the fiscal year ending 2026.)

Year-Over-Year Comparison

This filing pertains to the 2025 Annual Meeting, and direct year-over-year comparisons of financial metrics like revenue growth, margins, or net income are not available within this proxy statement itself. The DEF 14A focuses on corporate governance, director elections, and proposals for shareholder approval, rather than a detailed financial performance review against the prior year.

Filing Documents

• bglc_def14a.htm (DEF 14A) — 427KB
• 0001477932-25-008757.txt ( ) — 428KB

Executive Compensation

Executive Compensation 23

Security Ownership Of Certain Beneficial Owners And Management

Security Ownership Of Certain Beneficial Owners And Management 25 Householding of Proxy Materials 26 Other Matters 26 Where You Can Find Additional Information 26 Proxy Card and Voting Instructions

Forward-Looking Statements

Forward-Looking Statements This proxy statement (this "Proxy Statement") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Proxy Statement that do not relate to matters of historical fact should be considered forward-looking statements. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Proxy Statement, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, which is available on the Company's Investor Relations website at http://www.bionexusgenelab.com and on the SEC website at www.sec.gov . All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Proxy Statement. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances. Capitalized terms shall have the meanings ascribed to such terms in the Proxy Statement. 3 Table of Contents BIONEXUS GENE LAB CORP. PROXY STATEMENT ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 24, 2025 INFORMATION ABOUT THE ANNUAL MEETING AND VOTING General This Proxy Statement contains information related to the Annual Meeting of Stockholders (the "Annual Meeting") of BioNexus Gene Lab Corp. (the "Company," "we," "our" or "us"), which will be held on December 24, 2025, at 9:00 a.m., Eastern Time, and any postponements or adjournments thereof. We will host the Annual

View Full Filing

View this DEF 14A filing on SEC EDGAR